ID Source | ID |
---|---|
PubMed CID | 3035205 |
MeSH ID | M0115452 |
Synonym |
---|
ethylenediammineplatinum(ii) malonate |
nsc 146068 |
(ethane-1,2-diamine-n,n')(malonato(2-)-o,o')platinum |
malpen |
einecs 255-484-8 |
platinum, (1,2-ethanediamine-kappan,kappan')(propanedioato(2-)-kappao1,kappao3)-, (sp-4-2)- |
platinum, (1,2-ethanediamine-n,n')(propanedioato(2-)-o,o')-, (sp-4-2)- |
platinum (ii), (ethylenediammine)malonato- |
jm-40 |
ethylenediamine platinum(ii) malonate |
unii-9bt36e343a |
jm 40 |
malopen |
9bt36e343a , |
(sp-4-2)-(1,2-ethanediamine-.kappa.n1,.kappa.n2)(propanedioato(2-)-.kappa.o1,.kappa.o3)platinum |
malonatoethylenediamineplatinum(ii) |
platinum, (1,2-ethanediamine-.kappa.n,.kappa.n')(propanedioato(2-)-.kappa.o1,.kappa.o3)-, (sp-4-2)- |
platinum, (1,2-ethanediamine-.kappa.n1,.kappa.n2)(propanedioato(2-)-.kappa.o1,.kappa.o3)-, (sp-4-2)- |
(ethane-1,2-diamine-n,n')[malonato(2-)-o,o']platinum |
Q27895836 |
Excerpt | Reference | Relevance |
---|---|---|
" Calculated pharmacokinetic parameters (peak concentrations, half-lives, areas under the curve) were compared with the corresponding values in patients at the maximal tolerated dose." | ( Comparative pharmacokinetics of cisplatin and three analogues in mice and humans. Elferink, F; Klein, I; Pinedo, HM; van der Vijgh, WJ; van Hennik, MB; Vermorken, JB; Winograd, B, 1987) | 0.27 |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 9 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.15) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 9 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |